Register
Forgot your password?

The role of soluble ST2 as a marker of fibrosis in the diagnosis and prognosis of heart failure

Authors: Kremneva L.V.1 2, Gapon L.I.2, Shalaev S.V.1

Company: 1 Tyumen State Medical University of the Ministry of Health of Russia, Tyumen, Russia
2 Tyumen Cardiology Research Center, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tyumen, Russia

For correspondence:  Sign in or register.

Type:  Reviews


DOI: https://doi.org/10.24022/1997-3187-2025-19-2-155-161

For citation: Kremneva L.V., Gapon L.I., Shalaev S.V. The role of soluble ST2 as a marker of fibrosis in the diagnosis and prognosis of heart failure. Creative Cardiology. 2025; 19 (2): 155–161 (in Russ.). DOI: 10.24022/1997-3187-2025-19-2-155-161

Received / Accepted:  27.02.2025 / 10.03.2025

Keywords: acute and chronic heart failure soluble fibrosis marker ST2 diagnosis and prognosis of heart failure



Subscribe 🔒

 

Abstract

Heart failure (HF) is a common disease with an unfavorable prognosis. The diagnosis of HF, especially in early stages, is difficult due to the non-specific nature of its symptoms. Therefore, the possibility of using different laboratory markers for the diagnosis of HF is being investigated. This paper presents data from recent studies reflecting the diagnostic and prognostic value of the fibrosis marker soluble ST2 (sST2) in acute and chronic HF. It has been shown that sST2 can be used as an adjunct test in combination with natriuretic peptides for the diagnosis of HF. The data presented allow the use of sST2 to assess the risk of developing cardiovascular complications, including general and cardiac death, as well as the effectiveness of therapy in patients with HF.

References

  1. Savarese G., Becher P.M., Lund L.H., Seferovic P., Rosano G.M.C., Coats A.J.S. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc. Res. 2023; 118 (17): 3272–3287. DOI: 10.1093/cvr/cvac013
  2. Polyakov D.S., Fomin I.V., Belenkov Yu.N., Mareev V.Yu., Ageev F.T., Artemjeva E.G. et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021; 61 (4): 4–14 (in Russ.). DOI: 10.18087/cardio.2021.4.n1628
  3. Shlyakhto E.V., Belenkov Yu.N., Boytsov S.A., Villevalde S.V., Galyavich A.S., Glezer M.G. et al. Interim analysis of a prospective observational multicenter registry study of patients with chronic heart failure in the Russian Federation «PRIORITET-CHF»: Initial characteristics and treatment of the first included patients. Russian Journal of Cardiology. 2023; 28 (10): 5593 (in Russ.) DOI: 10.15829/1560-4071-2023-5593
  4. Karetnikova V.N., Kashtalap V.V., Kosareva S.N., Barbarash O.L. Myocardial fibrosis: Current aspects of the problem. Therapeutic Archive. 2017; 1: 88–93 (in Russ.). DOI: 10.17116/terarkh201789188-93
  5. Metra M., Tomasoni D., Adamo M., Bayes-Genis A., Fillippatos G., Abdelhamid M. et al. Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2023; 25 (6): 776–791. DOI: 10.1002/ejhf.2874
  6. Wong T.C., Piehler K., Meier C.G., Testa S.M., Klock A.M., Aneizi A.A. et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation. 2012; 126: 1206–1216. DOI: 10.1161/CIRCULATIONAHA.111.089409
  7. Sanada S., Hakuno D., Higgins L.J., Schreiter E.R., McKenzie A.N.S., Lee R.T. et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system JCI. J. Clin. Invest. 2007; 117 (6): 1538–1549. DOI: 10.1172/JCI30634
  8. Schmitz J. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type-2-associated cytokines. Immunity. 2005; 23: 479–490. DOI: 10.1016/j.immuni.2005.09.015
  9. Dieplinger B., Januzzi J.L., Steinmair M., Gabriel C., Poelz W., Haltmayer M., Mueller T. Analytical and clinical evaluation of a novel high- sensitivity assay for measurement of soluble ST2 in human plasma The PresageTM ST2 assay. Clinical Chimica Acta. 2009; 409: 33–40. DOI: 10.1016/j.cca.2009.08.010
  10. Zhang T., Xu C., Zhao R. Cao Z. Diagnostic value of sST2 in cardiovascular diseases: a systematic review and meta-analysis. Front. Cardio vasc. Meg. 2021; 8: 697837. DOI: 10.3389/fcvm.2021.697837
  11. Dattagupta A., Immaneni S. ST2: Current status. Indian Heart J. 2018; 70: S96–101. DOI: 10.1016/j.ihj.2018.03.001
  12. Coglianese E.E., Larson M.G.,Vasan R.S., Ho J.E., Ghorbani A., McCabe E.L. et al. Destribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin. Chem. 2012; 58: 1673–1681. DOI: 10.1373/clinchem.2012.192153
  13. Jin X.L., Huang N., Shang H., Zhou M.C., Hong Y., Cai W.Z., Huang J. Diagnosis of chronic heart failure by the soluble suppression of tumorigenicity 2 and N-terminal pro-brain natriuretic peptide. J. Clin. Lab. Anal. 2018; 32: e22295. DOI: 10.1002/jcla.22295
  14. Januzzi J.L., Peacock W.F., Maisel A.S., Chae C.U., Jesse R.L., Baggish A.L. et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J. Am. Coll. Cardiol. 2007; 50: 607–613. DOI: 10.1016/j.jacc.2007.05.014
  15. Mueller T., Jaffe A.S. Soluble ST2: Analytical considerations. Am. J. Cardiol. 2015; 115 (suppl 7): 88–218. DOI: 10.1016/amjcard.2015.01.035
  16. Songurov R.N. Soluble ST2 biomarker as a risk stratification toole in patients with heart failure. The Bulletin of Bakoulev Center. Cardiovascular Diseases. 2023; 24 (2): 97–106 (in Russ.). DOI: 10.24022/1810-0694-2023-24-2-97-106
  17. Boisot S., Beede J., Isakson S., Chiu A., Clopton P., Januzzi J. et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J. Card. Fail. 2008; 14 (9): 732–738. DOI: 10.1016/j.cardfail.2008.06.415
  18. Mueller T., Dieplinger B., Gegenhuber A., Poelz W., Pacher R., Haltmayer M. et al. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin. Chem. 2008; 54 (4): 752–756. DOI: 10.1373/clinchem.2007.096560
  19. Kopeva K.V., Grakova E.V., Tepliakov A.T. Novye marker serdechnoi nedostatochnosti: znachenie dlia diagnostiki I prognozirovaniia Nt- proBNP i interleikinovykh retseptorov-chlenov semeistva ST2. Kompleksnye problemy serdechno-sosudistykh zabolevanii. 2018; 7 (1): 94– 101 (in Russ.). DOI: 10.17802/2306-1278-2018-7-1-94-101
  20. Kohli P., Bonaca M.P., Kakkar R., Kudinova A.Y., Scirica B.M., Sabatine M.S. et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 Trial. Clin. Chem. 2012; 58 (1): 257–266. DOI: 10.1373/clinchem.2011.173369
  21. Zhang K., Zhang X.C., Mi Y.H., Liu J. Predicting value of serum soluble ST2 and interleukin-33 for risk stratification and prognosis in patients with acute myocardial infarction. Chin. Med. J. 2013; 126: 3628–3631. DOI: 10.3760/cma.j.issn.0366-6999.20130145
  22. Ji H., Yuan Z., Jiang W., Chen J. Long-term prognostic importance of high levels of sST2 in patients with AMI: a meta-analysis. Am. J. Transl. Res. 2024; 16 (1): 1–11. DOI: 10.62347/HAQL3794
  23. Ky B., French B., McCloskey K., Rame J.E., Mcintosh E., Shahi P. et al. High-sensitivity ST2 for prediction of adverse outcomes in Chronic Heart Failure. Circulation: Heart Failure. 2011; 4 (2): 180–187. DOI: 10.1161/CIRCHEARTFAILURE.110.958223
  24. Felker G.M., Fiuzat M., Thompson V., Shaw L.K., Neely M.L., Adams K.F. et al. Soluble ST2 in ambulatory patients with heart failure: association with functional capacity and long-term outcomes. Circulation: Heart Failure. 2013; 6 (6): 1172–1179. DOI: 10.1161/CIRCHEARTFAILURE.113.000207
  25. Aimo A., Vergaro G., Passino C., Ripoli A., Ky D., Miller W.L. et al. Prognostic value of soluble suppression of tumorigenicity-2 in chronic heart failure. JACC: Heart Failure. 2017; 5 (4): 280–286. DOI: 10.1016/j.jchf.2016.09.010
  26. Pascual-Figal D.A., Ordonez-Lanos J., Tornel P.L., Vazquez R., Puig T., Valdes M. et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J. Am. Coll. Cardiol. 2009: 54 (23): 2174–2179. DOI: 10.1016/j.jacc.2009.07.041
  27. Huang W.P., Zheng X., He L., Su X., Liu C.W., Wu M.X. et al. Role of soluble ST2 levels and beta-blockers dosage on cardiovascular events of patients with unselected st-segment elevation myocardial infarction. Clin. Med. J. 2018; 31 (11): 1282–1288. DOI: 10.4103/0366-6999.232819
  28. Skvortsov A.A., Narusov O.Yu., Muksinova M.D. Soluble ST2 – biomarker for prognosis and monitoring in decompensated heart failure. Kardiologia. 2019; 59 (11S): 18–27 (in Russ.). DOI: 10.18087/cardio.n765
  29. Thanikachalam P.V., Ramamurthy S., Sainath P.B., Radhakrishnan B. Repurposing of IL-33/ST2 modulating drugs as a cardioprotective agent: a promising approach. J. Pharm. Innovation. 2024; 19 (7): 94–104. DOI: 10.1007/s12247-024-09818-w

About Authors

  • Lyudmila V. Kremneva, Dr. Med. Sci., Professor; ORCID
  • Lyudmila I. Gapon, Dr. Med. Sci., Professor, Head of the Scientific Division of Clinical Cardiology; ORCID
  • Sergey V. Shalaev, Dr. Med. Sci., Professor, Corresponding Member of the Russian Academy of Sciences, Head of the Chair of Cardiology and Cardiac Surgery With a Course of Emergency Medical Care; ORCID

Chief Editor

Elena Z. Golukhova, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, Director of Bakoulev National Medical Research Center for Cardiovascular Surgery


Sort by